MESO - Mesoblast Limited
NASDAQ
->
Healthcare
->
Biotechnology
Melbourne,
Australia
Type: Equity
MESO price evolution
MESO
| (in millions $) | 30 Jul 2024 | 31 Jan 2024 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $62.56 | $77.14 | $70.92 | $48.4 |
| Short term investments | ||||
| Net receivables | $3.4 | $4 | $7 | $8.39 |
| Inventory | ||||
| Total current assets | $86.46 | $85.15 | $81.66 | $61.37 |
| Long term investments | ||||
| Property, plant & equipment | $3.84 | $5.5 | $6.49 | $7.13 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $669.15 | $670.28 | $669.41 | $650.44 |
| Current liabilities | ||||
| Accounts payable | $7.07 | $10.76 | $20.14 | $20.97 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $73.24 | $31.37 | $41.98 | $53.92 |
| Long term debt | $102.44 | $110.61 | $106.48 | $103.69 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $188.8 | $161.55 | $167.58 | $168.27 |
| Shareholders' equity | ||||
| Retained earnings | -$788.95 | -$736.91 | -$706.47 | -$685.62 |
| Other shareholder equity | -$40.22 | -$39.11 | -$0.54 | -$39.45 |
| Total shareholder equity | ||||
| (in millions $) | 30 Jul 2024 | 30 Jul 2023 | 30 Jul 2022 | 29 Jul 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $62.56 | $70.92 | $60.03 | $136.88 |
| Short term investments | ||||
| Net receivables | $3.4 | $7 | $4.4 | $4.84 |
| Inventory | ||||
| Total current assets | $86.46 | $81.66 | $69.84 | $148.23 |
| Long term investments | $1.76 | $2.08 | ||
| Property, plant & equipment | $3.84 | $6.49 | $9.96 | $3.02 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $596.49 | |||
| Total investments | ||||
| Total assets | $669.15 | $669.41 | $662.14 | $744.72 |
| Current liabilities | ||||
| Accounts payable | $7.07 | $20.14 | $23.08 | $19.6 |
| Deferred revenue | ||||
| Short long term debt | $5.02 | $53.2 | ||
| Total current liabilities | $73.24 | $41.98 | $51.37 | $94.27 |
| Long term debt | $102.44 | $106.48 | $98.7 | $41.05 |
| Total noncurrent liabilities | $69.05 | |||
| Total debt | ||||
| Total liabilities | $188.8 | $167.58 | $165.1 | $163.32 |
| Shareholders' equity | ||||
| Retained earnings | -$788.95 | -$706.47 | -$628.02 | -$647.57 |
| Other shareholder equity | -$40.22 | -$0.54 | -$0.54 | $65.81 |
| Total shareholder equity | $497.04 | $581.4 | ||
| (in millions $) | 30 Jul 2024 | 31 Jan 2024 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.51 | $3.39 | $2.14 | $1.94 |
| Cost of revenue | ||||
| Gross Profit | -$6.46 | -$3.36 | -$6.59 | -$4.31 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $37.04 | $20.03 | $11.5 | $9.56 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.09 | -$0.1 | -$0.04 | -$0.05 |
| Interest expense | -$9.78 | -$9.13 | -$4.51 | -$4.77 |
| Net income | ||||
| Net income | -$55.42 | -$32.54 | -$21.92 | -$18.6 |
| Income (for common shares) | ||||
| (in millions $) | 30 Jul 2024 | 30 Jul 2023 | 30 Jul 2022 | 29 Jul 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $5.9 | $7.5 | $10.21 | $7.46 |
| Cost of revenue | ||||
| Gross Profit | -$9.81 | -$20.23 | -$20.54 | -$25.26 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $57.07 | $42.49 | $53.22 | $64.37 |
| Operating income | -$88.92 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.19 | -$0.21 | -$0.24 | -$0.82 |
| Interest expense | -$18.91 | -$18.78 | -$17.44 | $10.71 |
| Net income | ||||
| Net income | -$87.96 | -$81.89 | -$91.35 | -$98.81 |
| Income (for common shares) | ||||
| (in millions $) | 30 Jul 2024 | 31 Jan 2024 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.1 | -$0.09 | -$0.19 | -$0.21 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $40.25 | $31.6 | $74.5 | $35.74 |
| Effect of exchange rate | -$0.06 | $1.3 | -$0.17 | -$0.19 |
| Change in cash and equivalents | -$8.36 | $6.24 | $10.87 | -$11.65 |
| (in millions $) | 30 Jul 2024 | 30 Jul 2023 | 30 Jul 2022 | 29 Jul 2021 |
|---|---|---|---|---|
| Net income | -$98.81 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$106.68 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.1 | -$0.19 | -$0.23 | -$1.65 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $40.25 | $74.5 | -$9.87 | $114.47 |
| Effect of exchange rate | -$0.06 | -$0.17 | -$0.55 | $1.42 |
| Change in cash and equivalents | -$8.36 | $10.87 | -$76.43 | $7.55 |
News
Fundamentals
| Market cap | $2.34B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 116.09M |
| Revenue | $9.98M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$128.47M |
| Revenue Q/Q | 17.81% |
| Revenue Y/Y | 26.76% |
| P/E ratio | -18.20 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 234.27 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.54 |
| EPS | -$1.11 |
|---|---|
| ROA | -19.32% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.18 |
| Quick ratio | N/A |